Cargando…

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourdin, Arnaud, Papi, Alberto A., Corren, Jonathan, Virchow, J. Christian, Rice, Megan S., Deniz, Yamo, Djandji, Michel, Rowe, Paul, Pavord, Ian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820970/ https://www.ncbi.nlm.nih.gov/pubmed/33010038 http://dx.doi.org/10.1111/all.14611

Ejemplares similares

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Asthma progression and mortality: the role of inhaled corticosteroids
por: O'Byrne, Paul, et al.
Publicado: (2019)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
por: Hanania, Nicola A, et al.
Publicado: (2022)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma
por: Beasley, Richard, et al.
Publicado: (2019)

Real-life effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid (ICS) in pediatric patients with uncontrolled asthma
por: Bérubé, Denis, et al.
Publicado: (2014)

Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study
por: Bérubé, Denis, et al.
Publicado: (2014)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Inhaled Corticosteroids and Adult Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2019)

High degree of supervision improves adherence to inhaled corticosteroids in children with asthma
por: Park, Geun Mi, et al.
Publicado: (2015)

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019)

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
por: Busse, William W., et al.
Publicado: (2021)

Asthma and Therapeutics: Inhaled Corticosteroids, Corticosteroid Osteoporosis, and the Risk of Fracture in Chronic Asthma
por: Toogood, John H
Publicado: (2005)

The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids
por: Martin, Matthew J., et al.
Publicado: (2020)

Inhaled corticosteroids in childhood asthma: the story continues
por: van Aalderen, Wim M. C., et al.
Publicado: (2010)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

The use of inhaled corticosteroids in pediatric asthma: update
por: Hossny, Elham, et al.
Publicado: (2016)

Effect of inhaled corticosteroids on systemic inflammation in asthma
por: Karthikeyan, Ramaraju, et al.
Publicado: (2014)

Inhaled corticosteroids: not just for asthma, but for COVID-19?
por: Liew, Felicity, et al.
Publicado: (2022)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
por: Lee, Ye Jin, et al.
Publicado: (2023)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
por: Price, David, et al.
Publicado: (2020)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Size of Inhaled Corticosteroid and Small Airway Inflammation in Asthma
por: Park, Choon-Sik
Publicado: (2017)

Inhaled Corticosteroids in Asthma: Promoting or Protecting Against Atherosclerosis?
por: Podgórski, Michał, et al.
Publicado: (2017)

Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma
por: Kim, Sang-Heon
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tbrs2ebeou6cjpc7h19em5j9r2